Selumetinib for Paediatric Patients: What This Means for Future Treatment?
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition.
More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
Pediatric
Pediatric Patients with CGvHD Ibrutinib OK'd by FDA
169 Views
Podcast-Peter Cole, MD @RutgersCancer @EmbraceKids @DanaFarber #ASH21 #PediatricALL #ALL #Cancer #Research Phase III...
Peter Cole, MD @RutgersCancer @EmbraceKids @DanaFarber #ASH21 #PediatricALL #ALL #Cancer #Research Phase III Clinica...
Brigitte Widemann, MD @CancerResearch @theNCI @NCI_CCR_PedOnc #PediatricCancer #PlexiformNeurofibromas #Cancer #Resea...
138 Views
Selumetinib for Paediatric Patients: What This Means for Future Treatment?
Selumetinib for Paediatric Patients: What About Adult Patients?
Selumetinib Approved for Paediatric Patients